Vivus Inc (VVUS) 1.05 $VVUS VIVUS Extends Return Date of

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 7:09 PM

Vivus Inc (VVUS) 1.05 $VVUS

VIVUS Extends Return Date of STENDRA Commercial Rights
Marketwired - Mon Aug 29, 3:30PM CDT
VIVUS and Auxilium Agree to Extend the STENDRA(R) (avanafil) U.S. and Canadian License Agreement Through September 30, 2016
VVUS: 1.05 (-0.01)

VIVUS Reports 2016 Second Quarter Financial Results
Marketwire Canada - Thu Aug 04, 3:15PM CDT
Management to Review Results and Provide Business Update in Conference Call Today at 4:30 p.m. Eastern Time
VVUS: 1.05 (-0.01)

VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
Marketwired - Wed Jul 27, 3:16PM CDT
MOUNTAIN VIEW, CA--(Marketwired - July 27, 2016) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero.
VVUS: 1.05 (-0.01)

Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.96 (-0.18), BIIB: 313.59 (+7.56), VVUS: 1.05 (-0.01), PTCT: 7.91 (+0.12)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.86 (-0.06), RTRX: 16.10 (-0.25), VVUS: 1.05 (-0.01), ARNA: 1.57 (+0.01)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
PR Newswire - Tue May 17, 10:31AM CDT
Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
VVUS: 1.05 (-0.01)

Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 16, 11:53AM CDT
Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015. VIVUS's stock price closed at $1.16 per share on May 13, 2016.
VVUS: 1.05 (-0.01)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (-0.02), INO: 9.08 (-0.06), VVUS: 1.05 (-0.01), TEVA: 51.22 (+0.32), ARNA: 1.57 (+0.01), PBYI: 57.48 (-1.23)

Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 6.32 (-0.13), JAZZ: 120.84 (-2.47), VVUS: 1.05 (-0.01), ARNA: 1.57 (+0.01)

Vivus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $12.7 million in its first quarter.
VVUS: 1.05 (-0.01)

Vivus Reports 2016 First Quarter Financial Results
Marketwired - Tue May 03, 3:05PM CDT
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"

, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2016. The net loss for the 2016 first quarter was $12.7 million as compared to $15.5 million in 2015. Cash, cash equivalents and available-for-sale securities was $227.8 million at March 31, 2016.
VVUS: 1.05 (-0.01)

VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
Marketwired - Tue Apr 19, 5:01PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.05 (-0.01)

Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 1.02 (unch), VVUS: 1.05 (-0.01), PETX: 8.81 (-0.11), GALE: 0.40 (unch)

VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.05 (-0.01)

Stocks to Trade: Those Looking Can Consider This List
ACCESSWIRE - Thu Mar 31, 10:59AM CDT
MIAMI, FL / ACCESSWIRE / March 31, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. VVUS, COOL, SKYS, and GNCA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 3.70 (-0.05), SKYS: 2.87 (-0.01), VVUS: 1.05 (-0.01), GNCA: 5.37 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AAR's Agreement with Airbus Elevates Repair Capabilities

A Strategic Play in the Aviation Game Alright, if you've been scanning the skies of the aviation aftermarket lately, AAR's recent maneuver ought to catch your eye. These folks have clinched a multi-year deal with Airbus Avionics, paving the runway for expanded radome repair capabilities. For those less acquainted with the inner workings of aviation, radomes protect those...

Cohen & Steers Sees Steady Rise in October AUM

Market Pushes Cohen & Steers Forward It's been a wild ride for financial managers lately, and Cohen & Steers, Inc. (NYSE: CNS) isn't exempt from the rollercoaster. As of October 31, 2026, they've reported assets under management (AUM) climbing to $99.6 billion—thanks to a hefty market appreciation of $4 billion. Not too shabby when you're dealing with the...

AppLovin Faces Fraud Lawsuit, Investors Alerted

AppLovin's Lawsuit: A Wake-Up Call for Investors The market never forgets, even if some investors might wish reality wasn’t so harsh. On the chopping block this time is AppLovin Corporation (NASDAQ: APP). Seems like their fairy tale with AI turned into a courtroom drama, one that’s throwing a real curveball on those rosy earnings expectations. What's the Case All...

Foundayo Aims to Revolutionize Sleep Apnea Treatment

Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...

Pak Mail Expands: Franchisee Adds Location Fast

Franchise Growth: Adding Another Brick When's the last time you heard of a franchisee eager enough to nab a second location? Well, that's exactly what's happening with Manny Zussman, who’s decided his Boulder Pak Mail outlet wasn’t keeping him busy enough. This entrepreneurial spirit's on full display as he's launching another Pak Mail over in Westminster, Colorado....

AssureTrace Brings Graham Clark on Board for Growth

Serialization's Fresh Outlook So, here we are—with one sharp mover joining the pack. Graham Clark is stepping into AssureTrace as the Chief Revenue Officer and Business Director. Another suit hopping on yet another board, but this time, it's got some seasoning we're looking at. Clark's packing over 23 years of serialization hustle, and that's not small change in the...

Upsher-Smith Rolls Out New Eye Solutions, Impacts Market

Upsher-Smith's Bold Move in Ophthalmics Right out of Maple Grove, Minnesota, Upsher-Smith Laboratories is shaking up the eye care scene with the launch of two strengths of Brimonidine Tartrate Ophthalmic Solution. We're talking 0.1% and 0.15%, folks. This ain't just a dribble in the ocean—these products are sailing into a $115 million market arena, according to IQVIA....

Navigating Simultaneous Home Buy and Sell Strategies

Juggling Two Housing Transactions You ever tried juggling chainsaws? That's what buying and selling your home at the same time can feel like. Selling First: Playing It Safe Some folks swear by selling their current home first, and there's good reason. It locks in your financial windfall, giving you a clear picture of your down payment and affordability. No more guessing...

Rainmaker's Cloud Seeding Milestone: Big Leap or Hype?

Pioneering Cloud Seeding: Rainmaker's Big Talk Mornings like this, I find myself wondering if we're still all buying snake oil—or if the future just landed in our laps. Rainmaker Technology Corporation just dropped what might be a game-changer or a grand illusion for those of us with a finger on the pulse of water tech. Their study in 'Atmosphere' paints a picture of...

Palmdale Expands Reach with Tri-County Acquisition

Fueling Up a New Chapter in Florida Once in a blue moon, you see a move that just clicks—and Palmdale Oil snapping up Tri-County Oil Distributors is that kind of slick deal. We're not talking about some Wall Street high-flyer here—this is down-to-earth business in North Central Florida, where local ties and trust still mean something. Why Tri-County Fits the Bill If...